Targeting the ubiquitin proteasome system in haematological malignancies

Blood Reviews

Volumn 27, Issue 6, 2013, Pages 297-304

  Crawford, Lisa J ^a   Irvine, Alexandra E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Proteasome inhibitors; Ubiquitin proteasome system

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DELANZOMIB; DEUBIQUITINATING ENZYME INHIBITOR; ENZYME INHIBITOR; HISTONE DEACETYLASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; IPSI 101; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; NEDD8 ACTIVATING ENZYME INHIBITOR; NSC 624206; OPROZOMIB; PEVONEDISTAT; PPZD 4409; PR 047; PR 924; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN FBXW7; PROTEIN MDM2; S PHASE KINASE ASSOCIATED PROTEIN 2; SALINOSPORAMIDE A; UBIQUITIN PROTEASOME SYSTEM; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E1; UBIQUITIN PROTEIN LIGASE E2; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONJUGATION; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR DYNAMICS; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RASH; STRUCTURE ACTIVITY RELATION; UBIQUITINATION;

PROTEASOME INHIBITORS; UBIQUITIN PROTEASOME SYSTEM;

HEMATOLOGIC NEOPLASMS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; UBIQUITIN;

EID: 84887611976     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.10.002     Document Type: Article

References (129)

1. Rahighi S., Dikic I. Selectivity of the ubiquitin-binding modules. FEBS Lett 2012, 586:2705-2710.
2. Duda D.M., Scott D.C., Calabrese M.F., Zimmerman E.S., Zheng N., Schulman B.A. Structural regulation of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol 2011, 21:257-264.
3. Groll M., Ditzel L., Lowe J., et al. Structure of 20S proteasome from yeast at 2.4Å resolution. Nature 1997, 386:463-471.
4. Groll M., Bajorek M., Kohler A., et al. A gated channel into the proteasome core particle. Nat Struct Biol 2000, 7:1062-1067.
5. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999, 17:739-779.
6. Sijts E.J., Kloetzel P.M. The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci 2011, 68:1491-1502.
7. Imajoh-Ohmi S., Kawaguchi T., Sugiyama S., Tanaka K., Omura S., Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995, 217:1070-1077.
8. Shinohara K., Tomioka M., Nakano H., Tone S., Ito H., Kawashima S. Apoptosis induction resulting from proteasome inhibition. Biochem J 1996, 317:385-388.
9. Drexler H.C. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci 1997, 94:855-860.
10. Orlowski R.Z., Eswara J.R., Lafond-Walker A., Grever M.R., Orlowski M., Dang C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998, 58:4342-4348.
11. Kumatori A., Tanaka K., Inamura N., et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci 1990, 87:7071-7075.
12. Jakob C., Egerer K., Liebisch P., et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007, 109:2100-2105.
13. Ma W., Kantarjian H., Bekele B., et al. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res 2009, 15:3820-3826.
14. Crawford L.J., Windrum P., Magill L., et al. Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol 2009, 37:357-366.
15. Crawford L.J., Walker B., Ovaa H., et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006, 66:6379-6386.
16. Lightcap E.S., McCormack T.A., Pien C.S., Chau V., Adams J., Elliott P.J. Proteasome inhibition measurements: clinical application. Clin Chem 2000, 46:673-683.
17. Crawford L.J., Irvine A.E., Gupta I A. Proteasome inhibitors in the treatment of multiple myeloma. Multiple Myeloma - An Overview 2012, 3-32.
18. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
19. Edwards C.M., Lwin S.T., Fowler J.A., et al. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol 2009, 84:268-272.
20. Nawrocki S.T., Bruns C.J., Harbison M.T., et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002, 1:1243-1253.
21. Terpos E., Heath D.J., Rahemtulla A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006, 135:688-692.
22. Heider U., Kaiser M., Muller C., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006, 77:233-238.
23. Giuliani N., Morandi F., Tagliaferri S., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110:334-338.
24. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
25. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
26. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
27. Kane R.C., Bross P.F., Farrell A.T., Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8:508-513.
28. Kane R.C., Farrell A.T., Sridhara R., Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006, 12:2955-2960.
29. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
30. Kapoor P., Ramakrishnan V., Rajkumar S.V. Bortezomib combination therapy in multiple myeloma. Semin Hematol 2012, 49:228-242.
31. Cavaletti G., Jakubowiak A.J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010, 51:1178-1187.
32. Mateos M.V., San Miguel J.F. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 2012, 3:117-124.
33. Moreau P., Karamanesht I.I., Domnikova N., et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012, 51:823-829.
34. Lu J., Hou J., Zhang C.Y., et al. The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2013, 34:309-312.
35. Petrucci M.T., Giraldo P., Corradini P., et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 2013, 160:649-659.
36. Taverna C., Voegeli J., Trojan A., Olie R.A., von Rohr A. Effective response with bortezomib retreatment in relapsed multiple myeloma-a multicentre retrospective survey in Switzerland. Swiss Med Wkly 2012, 142:w13562.
37. Wolf J., Richardson P.G., Schuster M., LeBlanc A., Walters I.B., Battleman D.S. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008, 6:755-760.
38. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5294.
39. Attar E.C., Johnson J.L., Amrein P.C., et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75years: CALGB (Alliance) study 10502. J Clin Oncol 2013, 31:923-929.
40. Attar E.C., Amrein P.C., Fraser J.W., et al. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res 2013, 37:1016-1020.
41. Blum W., Schwind S., Tarighat S.S., et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012, 119:6025-6031.
42. Messinger Y.H., Gaynon P.S., Sposto R., et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood 2012, 120:285-290.
43. Walker A.R., Klisovic R.B., Garzon R., et al. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2013, 10.3109/10428194.2013.833333.
44. Mohty M., Brissot E., Savani B.N., Gaugler B. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 2013, 19:1416-1420.
45. Groll M., Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 2004, 1695:33-44.
46. Kuhn D.J., Chen Q., Voorhees P.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
47. Demo S.D., Kirk C.J., Aujay M.A., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007, 67:6383-6391.
48. O'Connor O.A., Stewart A.K., Vallone M., et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009, 15:7085-7091.
49. Zangari M., Aujay M., Zhan F., et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 2011, 86:484-487.
50. Vij R., Siegel D.S., Jagannath S., et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012, 158:739-748.
51. Jagannath S., Vij R., Stewart A.K., et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012, 12:310-318.
52. Niesvizky R., Martin T.G., Bensinger W.I., et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013, 19:2248-2256.
53. Siegel D.S., Martin T., Wang M., et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120:2817-2825.
54. Siegel D., Martin T., Nooka A., et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. Haematologica 2013, 10.3324/haematol.2013.089334.
55. Herndon T.M., Deisseroth A., Kaminskas E., et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013, 19:4559-4563.
56. Kupperman E., Lee E.C., Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010, 70:1970-1980.
57. Chauhan D., Tian Z., Zhou B., et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011, 17:5311-5321.
58. Lee E.C., Fitzgerald M., Bannerman B., et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011, 17:7313-7323.
59. Macherla V.R., Mitchell S.S., Manam R.R., et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005, 48:3684-3687.
60. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8:407-419.
61. Singh A.V., Palladino M.A., Lloyd G.K., Potts B.C., Chauhan D., Anderson K.C. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol 2010, 149:550-559.
62. Chauhan D., Singh A., Brahmandam M., et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111:1654-1664.
63. Chauhan D., Singh A.V., Ciccarelli B., Richardson P.G., Palladino M.A., Anderson K.C. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010, 115:834-845.
64. Piva R., Ruggeri B., Williams M., et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008, 111:2765-2775.
65. Dorsey B.D., Iqbal M., Chatterjee S., et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008, 51:1068-1072.
66. Sanchez E., Li M., Steinberg J.A., et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 2010, 148:569-581.
67. Gallerani E., Zucchetti M., Brunelli D., et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2013, 49:290-296.
68. Zhou H.J., Aujay M.A., Bennett M.K., et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009, 52:3028-3038.
69. Roccaro A.M., Sacco A., Aujay M., et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010, 115:4051-4060.
70. Chauhan D., Singh A.V., Aujay M., et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010, 116:4906-4915.
71. Busse A., Kraus M., Na I.K., et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 2008, 112:659-670.
72. Niewerth D., Franke N.E., Jansen G., et al. Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica 2013, 10.3324/haematol.2013.092411.
73. Singh A.V., Bandi M., Aujay M.A., et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011, 152:155-163.
74. Kuhn D.J., Hunsucker S.A., Chen Q., Voorhees P.M., Orlowski M., Orlowski R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113:4667-4676.
75. Xu G.W., Ali M., Wood T.E., et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010, 115:2251-2259.
76. Pelzer C., Kassner I., Matentzoglu K., et al. UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 2007, 282:23010-23014.
77. Yang Y., Kitagaki J., Dai R.M., et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007, 67:9472-9481.
78. Ungermannova D., Parker S.J., Nasveschuk C.G., et al. Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J Biomol Screen 2012, 17:421-434.
79. Smith M.A., Maris J.M., Gorlick R., et al. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 2012, 59:246-253.
80. Milhollen M.A., Traore T., Adams-Duffy J., et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010, 116:1515-1523.
81. Swords R.T., Kelly K.R., Smith P.G., et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010, 115:3796-3800.
82. McMillin D.W., Jacobs H.M., Delmore J.E., et al. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther 2012, 11:942-951.
83. David Y., Ziv T., Admon A., Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines. J Biol Chem 2010, 285:8595-8604.
84. Chauhan D., Li G., Hideshima T., et al. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of bortezomib/proteasome inhibitor PS-341. Oncogene 2004, 23:3597-3602.
85. Eliseeva E., Pati D., Diccinanni M.B., et al. Expression and localization of the CDC34 ubiquitin-conjugating enzyme in pediatric acute lymphoblastic leukemia. Cell Growth Differ 2001, 12:427-433.
86. Ceccarelli D.F., Tang X., Pelletier B., et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 2011, 145:1075-1087.
87. Pulvino M., Liang Y., Oleksyn D., et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 2012, 120:1668-1677.
88. Abdul-Nabi A.M., Yassin E.R., Varghese N., Deshmukh H., Yaseen N.R. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS One 2010, 5:e12464.
89. Hendy O.M., Elghannam D.M., El-Sharnouby J.A., Goda E.F., El-Ashry R., Al-Tonbary Y. Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia. Hematology 2009, 14:335-340.
90. Xu-Monette Z.Y., Moller M.B., Tzankov A., et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy. Blood 2013, 10.1182/blood-2012-12-473702.
91. Liang M., Han X., Vadhan-Raj S., et al. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol 2010, 23:381-391.
92. Teoh G., Urashima M., Ogata A., et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 1997, 90:1982-1992.
93. Saha M.N., Qiu L., Chang H. Targeting p53 by small molecules in haematological malignancies. J Hematol Oncol 2013, 6. (23-8722-6-23).
94. Drakos E., Singh R.R., Rassidakis G.Z., et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia 2011, 25:856-867.
95. Manfe V., Biskup E., Johansen P., et al. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. J Invest Dermatol 2012, 132:1487-1496.
96. Saha M.N., Jiang H., Chang H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Cancer Biol Ther 2010, 10:567-578.
97. Carol H., Reynolds C.P., Kang M.H., et al. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2013, 60:633-641.
98. Kojima K., Burks J.K., Arts J., Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 2010, 9:2545-2557.
99. Jones R.J., Chen Q., Voorhees P.M., et al. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage-independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 2008, 14:5416-5425.
100. Jones R.J., Baladandayuthapani V., Neelapu S., et al. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 2011, 118:4140-4149.
101. Sosin A.M., Burger A.M., Siddiqi A., Abrams J., Mohammad R.M., Al-Katib A.M. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol 2012, 5:57.
102. Fulda S. Inhibitor of apoptosis proteins in haematological malignancies. Leukemia 2009, 23:467-476.
103. Ansell S.M., Arendt B.K., Grote D.M., et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004, 18:616-623.
104. Houghton P.J., Kang M.H., Reynolds C.P., et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2012, 58:636-639.
105. Ramachandiran S., Cain J., Liao A., et al. The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. Leuk Res 2012, 36:784-790.
106. Luck S.C., Russ A.C., Botzenhardt U., et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia 2011, 25:1728-1738.
107. Schimmer A.D., Estey E.H., Borthakur G., et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009, 27:4741-4746.
108. Min Y.H., Cheong J.W., Lee M.H., et al. Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis. Clin Cancer Res 2004, 10:5123-5130.
109. Andreu E.J., Lledo E., Poch E., et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005, 65:3264-3272.
110. Zhan F., Colla S., Wu X., et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007, 109:4995-5001.
111. Chen Q., Xie W., Kuhn D.J., et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008, 111:4690-4699.
112. Chan C.H., Morrow J.K., Li C.F., et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 2013, 154:556-568.
113. Pavlides S.C., Huang K.T., Reid D.A., et al. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. Endocrinology 2013, 10.1210/en.2013-1757.
114. Ungermannova D., Lee J., Zhang G., Dallmann H.G., McHenry C.S., Liu X. High-throughput screening AlphaScreen Assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1. J Biomol Screen 2013, 18:910-920.
115. Wu L., Grigoryan A.V., Li Y., Hao B., Pagano M., Cardozo T.J. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol 2012, 19:1515-1524.
116. Thompson B.J., Jankovic V., Gao J., et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 2008, 205:1395-1408.
117. Akhoondi S., Sun D., von der Lehr N., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012.
118. Thompson B.J., Buonamici S., Sulis M.L., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007, 204:1825-1835.
119. O'Neil J., Grim J., Strack P., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007, 204:1813-1824.
120. King B., Trimarchi T., Reavie L., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
121. Reavie L., Buckley S.M., Loizou E., et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 2013, 23:362-375.
122. Schwickart M., Huang X., Lill J.R., et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-107.
123. Sun H., Kapuria V., Peterson L.F., et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 2011, 117:3151-3162.
124. Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010, 38:137-143.
125. Chauhan D., Tian Z., Nicholson B., et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012, 22:345-358.
126. Wang M., Martin T., Bensinger W., et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013, 10.1182/blood-2013-07-511170.
127. Gupta N., Saleh M., Venkatakrishna K. Flat-dosing versus BSA-based dosing for MLN9708, an investigational proteasome inhibitor: population pharmacokinetic (PK) analysis of pooled data from 4 Phase-1 studies. Blood 2011, 118:1433.
128. Richardson P.G., Spencer A., Cannell P., et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). Blood 2011, 118:302.
129. Savona M., Berdeja J., Lee S. A Phase 1b dose-escalation study of split-dose oprozomib (ONX0912) in patients with hematologic malignancies. Blood 2012, 120:203.